Results 171 to 180 of about 567,668 (313)
Dopamine agonist withdrawal in hyperprolactinemia: when and how [PDF]
Roberto Salvatori
openalex +1 more source
G. Dichiara, A. Imperato
semanticscholar +1 more source
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang +18 more
wiley +1 more source
Cholesterol-activated stress granules reduce the membrane localization of DRD2 and promote prolactinoma dopamine agonists resistance. [PDF]
Peng Y +8 more
europepmc +1 more source
Abstract Background and Purpose Lactate, historically viewed as a metabolic by‐product, has emerged as a signalling molecule via the G protein–coupled receptor Hydroxycarboxylic Acid Receptor 1 (HCAR1). The receptor is primarily expressed in adipocytes but also found in various other tissues.
Simon Lind +6 more
wiley +1 more source
Dopamine agonists both stimulate and inhibit prolactin release in GH4ZR7 cells [PDF]
Annisa Chang, Shin Sh
openalex +1 more source
M. Poletti, U. Bonuccelli
semanticscholar +1 more source
A role for epithelium‐derived 6‐nitrodopamine on human ureter contractility
Abstract Background and Purpose To investigate the basal release of 6‐nitrodopamine (6‐ND) from human isolated ureter and the role of this novel catecholamine in the ureter contractility. Experimental Approach Ureters from 67 brain‐dead organ donors (40 males and 27 females) were used during kidney transplantation procedures.
Wilmar Azal Neto +12 more
wiley +1 more source
Dopamine Agonists as a Novel "Cure" for Autoimmune Diabetes. [PDF]
Sahota S +3 more
europepmc +1 more source

